Developing
next-generation precision medicines
Exploiting genomic instability and replication stress to deliver significant advancements to cancer patients harbouring metabolic vulnerabilities.
Our mission
Nodus Oncology is developing first- and best-in-class molecules inhibiting the damage response and replication stress response
Founded by Cumulus Oncology, and in partnership with the Lead Discovery Center, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly-defined cancer patient populations.
Our inhibitors induce DNA gaps and replication stress, leading to cancer cell death by replication catastrophe
PARGi
Best-in-class PARG inhibitor – Exploiting DNA repair in tumours with specific vulnerabilities
NOD1
First-in-class DNA replication inhibitor – Novel mode of action to induce replication stress
Latest news
Latest news and press releases from Nodus Oncology
